New hope for rare HIV-2: drug combo shows promise

This study tested a three-drug combination (raltegravir, emtricitabine, and tenofovir) as a first treatment for people with HIV-2, a less common form of HIV found mainly in West Africa. The goal was to see if this combination could control the virus better than standard treatments. Thirty participants who had never taken HIV drugs before were followed for 48 weeks to check if the treatment kept virus levels low and boosted immune cells.